Literature DB >> 15265118

Pregnancy outcomes after recovery from thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.

Sara K Vesely1, Xiaoning Li, J R McMinn, Deirdra R Terrell, James N George.   

Abstract

BACKGROUND: Recurrent thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) during a subsequent pregnancy is an important concern because pregnancy may increase the risk for relapse. STUDY DESIGN AND METHODS: Outcomes of all pregnancies after recovery from TTP-HUS in the Oklahoma TTP-HUS Registry, a cohort of 301 consecutive patients during the period of 1989 through 2003, were assessed and compared to the total published experience.
RESULTS: In the Oklahoma Registry, 3 of 7 (43%) women with idiopathic TTP-HUS, 2 of 11 (18%) women who were pregnant/postpartum, and 0 of 1 (0%) woman with a bloody diarrhea prodrome at their initial presentation were diagnosed with TTP-HUS during a subsequent pregnancy; all 5 women recovered. In published reports, 10 of 11 (91%) women with idiopathic TTP-HUS and 11 of 18 (61%) women who were pregnant/postpartum at their initial presentation, and all 11 (100%) women with congenital TTP-HUS were diagnosed with TTP-HUS during a subsequent pregnancy. Rates of recurrence in the Oklahoma Registry may be less because of case report bias for exceptional patients. Recurrent TTP-HUS was difficult to diagnose because other pregnancy-related complications were frequent.
CONCLUSIONS: Although pregnancies in these women were often complicated, a future pregnancy may be a safe and appropriate decision for women who have recovered from TTP-HUS.

Entities:  

Mesh:

Year:  2004        PMID: 15265118     DOI: 10.1111/j.1537-2995.2004.03422.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  16 in total

Review 1.  Thrombocytopenia in pregnancy.

Authors:  Douglas B Cines; Lisa D Levine
Journal:  Blood       Date:  2017-06-21       Impact factor: 22.113

2.  Multidisciplinary approach in pregnancy-associated thrombotic thrombocytopenic purpura: a case report.

Authors:  Gaetano Lucania; Emanuele Camiolo; Maria G Carmina; Teresa Fiandaca; Alessandro Indovina; Alessandra Malato; Renato Messina; Francesco Fabbiano; Raimondo Marcenò
Journal:  Blood Transfus       Date:  2013-07-11       Impact factor: 3.443

3.  Pregnancy-associated atypical haemolytic uraemic syndrome in the postpartum period: a case report and review of the literature.

Authors:  M Egbor; A Johnson; F Harris; D Makanjoula; H Shehata
Journal:  Obstet Med       Date:  2011-06-09

Review 4.  Thrombocytopenia in pregnancy.

Authors:  Douglas B Cines; Lisa D Levine
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

5.  Pregnancy outcomes following recovery from acquired thrombotic thrombocytopenic purpura.

Authors:  Yang Jiang; Jennifer J McIntosh; Jessica A Reese; Cassandra C Deford; Johanna A Kremer Hovinga; Bernhard Lämmle; Deirdra R Terrell; Sara K Vesely; Eric J Knudtson; James N George
Journal:  Blood       Date:  2014-01-07       Impact factor: 22.113

6.  Attending rounds: microangiopathic hemolytic anemia with renal insufficiency.

Authors:  William F Clark; Ainslie Hildebrand
Journal:  Clin J Am Soc Nephrol       Date:  2011-12-22       Impact factor: 8.237

7.  Thrombocytopenia in Pregnancy.

Authors:  Anca Marina Ciobanu; Simona Colibaba; Brandusa Cimpoca; Gheorghe Peltecu; Anca Maria Panaitescu
Journal:  Maedica (Bucur)       Date:  2016-03

Review 8.  Pathophysiology of thrombotic thrombocytopenic purpura.

Authors:  Han-Mou Tsai
Journal:  Int J Hematol       Date:  2010-01       Impact factor: 2.490

9.  Dengue Virus Infection Triggering Thrombotic Thrombocytopenic Purpura in Pregnancy.

Authors:  Surendran Deepanjali; Raghuramulu R Naik; Sharada Mailankody; Sivamani Kalaimani; Tamilarasu Kadhiravan
Journal:  Am J Trop Med Hyg       Date:  2015-08-17       Impact factor: 2.345

Review 10.  Thrombotic thrombocytopenic purpura: a thrombotic disorder caused by ADAMTS13 deficiency.

Authors:  Han-Mou Tsai
Journal:  Hematol Oncol Clin North Am       Date:  2007-08       Impact factor: 3.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.